Drug-Eluting Stent Wars Reach Standoff In Diabetic Patients
This article was originally published in The Gray Sheet
Executive Summary
The largest comparison to date of paclitaxel-versus sirolimus-eluting stents in diabetic patients failed to show a statistically significant difference in outcomes between the two devices, according to findings unveiled March 12 at the American College of Cardiology's annual meeting in Atlanta